康宁杰瑞(09966.HK)升幅扩至17%逼近高位 交投活跃
将於今年美国临床肿瘤学会年会呈列肿瘤免疫特效药及乳腺癌两种新药双特异性抗体研究结果的康宁杰瑞制药-B(09966.HK)下周五(28日)起正式获纳入MSCI中国小型股指数,该股今天急涨,尤其是午後升幅扩大,最高见21.7元,仅次於去年5月所创上市高位24.15元,现造21.05元,急涨17%,成交增至1,311万股,涉资2.64亿元。
康宁杰瑞昨天公布,将於2021年美国临床肿瘤学会年会呈列KN046(一种重组人源化PD-L1/CTLA-4双特异性抗体)及KN026(一种基於Fc的抗HER2双特异性抗体)研究结果。KN046的临床前及临床试验结果展现出良好有效性,并表明其有望降低脱靶毒性,该药品旨在被开发为突破性肿瘤免疫特效药。KN026正在中国及美国分别进行数项I/II期及一项I期临床试验,该药品已在晚期HER2+乳腺癌及GC/GEJ 患者中表现出良好初步疗效。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.